Immunomodulatory and Physical Effects of Phospholipid Composition in Vaccine Adjuvant Emulsions Authors
First Online: 14 March 2012 Received: 09 December 2011 Accepted: 28 February 2012 DOI:
Cite this article as: Fox, C.B., Baldwin, S.L., Duthie, M.S. et al. AAPS PharmSciTech (2012) 13: 498. doi:10.1208/s12249-012-9771-x Abstract
Egg phosphatidylcholine is commonly used as an emulsifier in formulations administered parenterally. However, synthetic phosphatidylcholine (PC) emulsifiers are now widely available and may be desirable substitutes for egg-derived phospholipids due to stability, purity, and material source considerations. In earlier work, we demonstrated that a squalene–1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) emulsion provided equivalent physical stability compared to a squalene–egg PC emulsion. In the present manuscript, we evaluate the physical stability of vaccine adjuvant emulsions containing a range of other synthetic phosphatidylcholine emulsifiers. Besides the POPC emulsion, the 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) emulsion showed good particle size and visual stability compared to emulsions made with other synthetic phospholipids. Moreover, comparable immune responses were elicited by squalene emulsions employing various synthetic PC or egg PC emulsifiers in combination with an inactivated influenza vaccine or a recombinant malaria antigen, and these responses were generally enhanced compared to antigen without adjuvant. Therefore, we show that (1) some synthetic PCs (DMPC, POPC, and to a lesser extent 1,2-dioleoyl-sn-glycero-3-phosphocholine) are effective stabilizers of squalene emulsion over a range of storage temperatures while others are not (1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, and 1,2-dilauroyl-sn-glycero-3-phosphocholine) and (2) the immunogenicity of stable squalene emulsions is similar regardless of PC source.
Key words oil-in-water emulsion phosphatidylcholine squalene vaccine adjuvant Electronic supplementary material
The online version of this article (doi:
) contains supplementary material, which is available to authorized users. 10.1208/s12249-012-9771-x References
Fox CB. Squalene emulsions for parenteral vaccine and drug delivery. Molecules. 2009;14:3286–312.
Reddy LH, Couvreur P. Squalene: a natural triterpene for use in disease management and therapy. Adv Drug Del Rev. 2009;61:1412–26.
Brito LA, Chan M, Baudner B, Gallorini S, Santos G, O’Hagan DT,
. An alternative renewable source of squalene for use in emulsion adjuvants. Vaccine. 2011;29:6262–8.
Yang YW, Wu CA, Morrow WJW. Cell death induced by vaccine adjuvants containing surfactants. Vaccine. 2004;22:1524–36.
Forchielli ML, Bersani G, Tala S, Grossi G, Puggioli C, Masi M. The spectrum of plant and animal sterols in different oil-derived intravenous emulsions. Lipids. 2010;45:63–71.
Vernooij EAAM, Kettens-van den Bosch JJ, Crommelin DJA. Rapid determination of acyl chain position in egg phosphatidylcholine by high-performance liquid chromatography/electrospray mass spectrometry. Rapid Comm Mass Spec. 1998;12:83–6.
de Man JM. Chemical and physical properties of fatty acids. In: Chow CK, editor. Fatty acids in foods and their health implications. Boca Raton: CRC Press; 2008. p. 17–46.
Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine. 2011;29:9563–72.
Fox CB, Lin S, Sivananthan SJ, Dutill TS, Forseth KT, Reed SG,
. Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions. Pharm Dev Technol. 2011;16:511–9.
Hilleman MR. Personal historical chronicle of six decades of basic and applied research in virology, immunology, and vaccinology. Immunol Rev. 1999;170:7–27.
Rosenberg SA, Yang JC, Kammula US, Hughes MS, Restifo NP, Schwarz SL,
. Different adjuvanticity of incomplete Freund’s adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. J Immunother. 2010;33:626–9.
Bock TK, Muller BW. A novel assay to determine the hemolytic activity of drugs incorporated in colloidal carrier systems. Pharm Res. 1994;11:589–91.
Baldwin SL, Shaverdian N, Goto Y, Duthie MS, Raman VS, Evers T,
. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine. 2009;27:5956–63.
Amselem S, Zawoznik E, Yogev A, Friedman D. Emulsomes, a new type of lipid assembly. In: Barenholz Y, Lasic DD, editors. Handbook of Nonmedical Applications of Liposomes: From design to microreactors. New York: CRC Press. 1995;209–23.
Vernooij EAAM, Brouwers JFHM, Kettenes-van den Bosch JJ, Crommelin DJA. RP-HPLC/ESI MS determination of acyl chain positions in phospholipids. J Sep Sci. 2002;25:285–9.
Fox CB, Uibel RH, Harris JM. Detecting phase transitions in phosphatidylcholine vesicles by Raman microscopy and self-modeling curve resolution. J Phys Chem B. 2007;111(39):11428–36.
Falsey AR. Half-dose influenza vaccine. Arch Intern Med. 2008;168:2402–3.
Yasuda T, Dancey GF, Kinsky SC. Immunogenicity of liposomal model membranes in mice: dependence on phospholipid composition. Proc Natl Acad Sci. 1977;74:1234–6.
Baudner BC, Ronconi V, Casini D, Tortoli M, Kazzaz J, Singh M,
. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res. 2009;26:1477–85.
Mikrut B. Case study: formulation of an intravenous fat emulsion. In: Burgess DJ, editor. Injectable dispersed systems: formulation, processing, and performance. Boca Raton: Taylor and Francis; 2005. p. 415–25.
Yoon JK, Burgess DJ. Interfacial properties as stability predictors of lecithin-stabilized perfluorocarbon emulsions. Pharm Dev Tech. 1996;1:333–41.
Kabalnov A, Tarara T, Arlauskas R, Weers J. Phospholipids as emulsion stabilizers: phase behavior
versus emulsion stability. J Coll Inter Sci. 1996;184:227–35.
Mollet H, Grubenmann A. Formulation technology: emulsions, suspensions, solid forms. New York: Wiley; 2001.
Nii T, Ishii F. Properties of various phosphatidylcholines as emulsifiers or dispersing agents in microparticle preparations for drug carriers. Colloids Surf B: Biointerfaces. 2004;39(1–2):57–63.
Fox CB, Anderson RC, Dutill TS, Goto Y, Reed SG, Vedvick T. Monitoring the effects of component structure and source and formulation stability and adjuvant activity of oil-in-water emulsions. Colloids Surf B: Biointerfaces. 2008;65:98–105.
Bibette J, Morse DC, Witten TA, Weitz DA. Stability criteria for emulsions. Phys Rev Lett. 1992;69(16):2439.
Capek I. Degradation of kinetically-stable o/w emulsions. Adv Coll Inter Sci. 2004;107(2–3):125–55.
Dalgleish DG. Adsorption of protein and the stability of emulsions. Trends Food Sci Technol. 1997;8(1):1–6.
McClements DJ. Critical review of techniques and methodologies for characterization of emulsion stability. Crit Rev Food Sci Nutr. 2007;47:611–49.
Tatulian SA. Binding of alkaline-earth metal cations and some anions to phosphatidylcholine liposomes. Eur J Biochem. 1987;170:413–20.
Tatulian SA. Effect of lipid phase transition on the binding of anions to dimyristoylphosphatidylcholine liposomes. Biochim Biophys Acta. 1983;736:189–95.
Tanaka Y, Mashino K, Inoue K, Nojima S. Mechanism of human erythrocyte hemolysis induced by short-chain phosphatidylcholines and lysophosphatidylcholine. J Biochem. 1983;94:833–40.
PubMed Copyright information
© American Association of Pharmaceutical Scientists 2012